Introduction: To estimate the value of interventions in multiple sclerosis (MS) -where lifetime costs and outcomes cannot be observed -outcome data have to be combined with costs. This requires that cost data be regularly updated.
Introduction
The role of economic studies in healthcare in Switzerland is less important than in some other European countries. The Swiss law stipulates that medical treatments have to be covered by the compulsory health insurance scheme if they are considered 'effective', 'appropriate' and 'cost-effective'. The methods required to assess cost-effectiveness for new and existing drugs are reference pricing (with a basket of nine European countries) and a comparative assessment of the therapeutic benefit to justify the price set by the manufacturer. Economic evaluations are accepted in a manufacturer submission yet not mandatory. Nevertheless, cost-of illness studies as a basis for health policy have the same importance as elsewhere.
The availability of disease-modifying treatments (DMTs) has led to changes in patient management and a focus on earlier and better diagnosis and adjustments in the diagnostic criteria themselves. One of the consequences in this regard is that the recorded prevalence of the disease is quite different from that estimated two or three decades ago. 1 In Switzerland, the current prevalence is estimated at 110 per 100,000, corresponding to a total of 10,000 individuals suffering from multiple sclerosis (MS). 2, 3 With diagnosis already possible after a clinically isolated event, 4 one must also expect a different distribution of the type of MS and the severity of the disease than 10 years ago: a larger proportion of patients with relapsing-remitting disease and thus of patients in the early stages of the disease and with less disability.
It is therefore important to update the information on the burden of MS, and the study presented here is part of a European-wide effort to update information on the burden of illness of MS in 16 countries, endorsed by the European Platform of MS Societies (EMSP) 5 and carried out with the support of national MS societies. It uses a similar methodology as the last European survey in 2005 that also included Switzerland. [6] [7] [8] 
Materials and methods
The detailed methodology for the European survey is published separately. 8 We therefore only provide a short summary of the general methods and issues specific to Switzerland.
Data
The study aimed to estimate the costs of all healthcare and other resource utilisation related to MS: hospitalisation, rehabilitation, consultations, diagnostic procedures and tests, medication, community care, family support and production losses (sick leave, early retirement, invalidity). In addition, information on major symptoms such as fatigue and cognition, healthrelated quality of life (HRQoL) as well as selfassessed disability using descriptions based on the Expanded Disability Status Scale (EDSS) was collected.
Data were collected with a standard questionnaire (translated into the three main Swiss languages, German, French and Italian), at a single point in time, for a retrospective period of time. The latter was varied depending on the question to minimise recall bias: 1 month for use of drugs, community services and family help; 3 months for hospitalisation, consultations, tests, sick leave and relapses; 12 months for major investments. Resource utilisation is reported for these time periods, while cost calculations are annualised.
Disease information such as the type of MS, disability (EDSS), HRQoL, utility (EuroQol five dimensions (EQ-5D) 9 ), symptoms (fatigue, cognitive difficulties) and the effect of MS on work related to the current week. For comparability across countries, 5 utilities are estimated with the original value set developed in the United Kingdom. 10 A number of countries have subsequently produced a local value set, but in Switzerland no specific tariff is available (although currently in development) and generally the UK or the German tariff is used.
The handling of missing data for the cost calculation is explained in more detail in the article describing the methods. 8 For resource use, we present actual answers without any imputation for missing responses. Also, no imputations are made for missing information on disease status, symptoms and HRQoL.
Costs
The costs are calculated from the societal perspective, including all costs regardless of who ultimately is responsible for them. Patient co-payments and patients' out-of-pocket expenses are thus included. The cost of a relapse is calculated as the difference in quarterly costs between patients with or without a relapse and an EDSS score between 0 and 6; patients who were unsure were excluded from the estimation. Invalidity, early retirement and DMT costs are not considered in this calculation, as these are unlikely to be affected within 3 months.
The unit costs for the individual resources were taken from public sources and are reported in the paper on methodology, 8 and the results are reported in Swiss Francs (2015).
Patients
The objective was to include a sample where all levels of disability (defined by EDSS) were represented in sufficient numbers to permit analysis, rather than a prevalence sample. This highlights how costs and HRQoL change as the disease progresses and provides the necessary data for cost-effectiveness analysis of treatments that are expected to change the course of the disease. However, it does not guarantee a representative sample, and the mean results may thus not be representative and should neither be extrapolated to national costs nor be compared to the results in earlier studies without appropriate adjustment. We therefore report the results by disease severity groups only (mild MS EDSS 0-3, moderate MS EDSS 4-6.5 and severe MS EDSS 7-9).
Data collection
In anonymous surveys, participation will depend heavily on the methods used for the survey: collecting data in MS centres tends to over-estimate the number of patients with early but severe disease and on treatment with DMTs; 11 collecting data from members of patient organisations may lead to the opposite and depend on the structure and activities of that organisation. Internet surveys will bias towards younger patients with better education.
The Swiss participants in the study were members of the Swiss MS Society (SMSG), and all but six responded to the survey on-line. The data were collected during the first quarter of 2016, after approval by the institutional review board of the University of Basel. The MS society invited 2800 individuals by e-mail, and the response rate reached 26%.
Results
A total of 721 evaluable responses were received, 99% on-line, which reduced the number of missing data considerably as a majority of answers were mandatory to continue responding. Respondents from the German-speaking part of the country represented 73%, from the French-speaking part 24% and from the Italian-speaking part 3%. Thus, German-speaking patients are slightly overrepresented (63% of the Swiss population speak German), while Italianspeaking patients are underrepresented (8% of the population speak Italian). Patients from all cantons participated and the geographical distribution was very close to the proportion of inhabitants, with the exception of the Zurich area with a high number of answers and the cities of Bern and Geneva and the canton of Ticino with a lower number than expected. 12 Table 1 provides details on demographics, employment and disease.
Demographics and employment
The age of respondents in Switzerland ranged from 20 to 81 years (mean 48.4 years, median 48 years, standard deviation (SD) 11.9 years). Women represented 74% of the sample; 72% lived with their family and nine patients (1%) lived in a nursing home at the time of the survey. Education levels in our sample were slightly higher than in the general population of that age group, likely due to the electronic data collection: 5% of patients had basic education, 71% a secondary or a professional degree and 23% a university degree. This compares to 12% of the population between 25 and 65 years with a basic degree, 61% with upper secondary education and 27% with tertiary education. 13 The majority of patients in the sample were below retirement age (defined as effective retirement age, 64.5 years for women and 66.1 years for men 14 ): 648 patients (90%). Of these, 418 patients (64.5%) were employed or self-employed. One patient above the retirement age also worked, bringing this group to 419 patients (or 58% of the full sample), with a mean age of 43.6 years. This compares to an employment rate of 81.5% in the general population age 16-64 years in 2015. 13 Twenty-three patients (6%) were on long-term sick leave at the time of the survey, for 9 months on average. In addition, all patients worked part-time, on average around 21 hours per week, and half of them did so because of MS. In the general population, only 31.2% of the employed work parttime (defined as <90%). 15 Sick leave during the past 3 months was reported by 40 patients, with a mean duration of 12.4 days. The average absence for sick leave in the general population is 6.5 days per year. 16 Employment decreased rapidly with advancing disease, as shown in Figure 1 . Of non-employed patients, three quarters indicated MS as the reason.
A large number of patients (68%) felt that MS affected their productivity at work and only 17% indicated that they had no problems, while 15% had not answered the question. The severity of the effect covered the entire visual analogue scale (VAS) range from 0 to 10, with a mean of 3.0 (SD 2.7; Figure 2 ). Fatigue was considered the most bothersome symptom (71%), followed by difficulties thinking (35%), pain (28%), mobility (22%) and low mood (14%).
Disease information
Disease information is summarised in Table 1 . The mean EDSS in the sample was 3.1 (SD 2.5), and EDSS scores covered the entire range evenly, with the exception of EDSS 9 (three patients only). The sample included a majority of patients with mild disease, but all groups were sufficiently large for analysis: The mild group represented 61% of the sample, the moderate group 26% and the severe group 12%.
The proportion of patients with relapsing-remitting MS (RRMS) was 61%, with secondary progressive MS (SPMS) was 18% and with primary progressive MS (PPMS) was 17% (5% missing). The proportion of patients with PPMS is somewhat higher than what would be expected and what has been found in recent studies 1, 17 and suggests, as we found in previous studies, that patients were insecure in their answers regarding the type of disease. We therefore did not include the disease type in our analyses and focus on EDSS levels instead. Consistent with this population of patients with predominantly RRMS and early disease, DMTs were used by 64% of the patients, with usage declining with higher EDSS levels, as expected ( Table 1) . Among DMT users, 29% were on their first treatment and first-generation DMTs were used by 35% ( Table 2) .
Relapses in the preceding 3 months were reported by 49 patients (7%), of which 39% occurred in the past month (Table 1) . However, 147 patients (20%) were unsure whether they had a relapse or not, and we assumed that the answer was no. Thus, the mean relapse rate over a 3-month period was estimated at 0.1 (SD 0.3). Corticosteroids were administered to 35 patients (18%) with relapses, predominantly as infusions (26 patients).
Symptoms and HRQoL
Fatigue and cognitive difficulties were an issue for a majority of patients, and both were related to disease severity (Figure 2 ). Fatigue was present in 93% of patients. The mean VAS score was 4.8 (SD 2.6) for the sample, 4.6 for patients with mild disease, 5.2 for patients in the moderate group and 5.1 for patients in the severe group. Cognitive difficulties were recognised by 64% of all patients. The mean VAS score in this group was 4.1 (SD 2.0) overall, 3.9 in the mild, 4.3 in the moderate and 4.9 in the severe group. For the full study sample (assigning 0 to the group with no problems), the mean score was 2.6 (2.4, 3.0 and 2.6, respectively, for the three groups).
The detailed answers to the EQ-5D indicated that both the severity and the domains affected changed with advancing disease. Self-care was unaffected in patients with mild disease, but declined very rapidly with advancing disease; mobility, pain and usual activities presented problems for almost all patients already in moderate disease; most noticeably, anxiety/ depression was present in 40%-50% of patients at all levels of disease severity (Figure 3 ).
Utility
The utility declined with increasing disability (EDSS; Figure 4 ). The mean utility in this specific sample of patients was 0.695 (0.708 for women and 0.657 for men).
Resource utilisation
Resource utilisation is presented in Table 3 . Hospitalisation was concentrated in a small group with, however, a relatively high frequency and long duration. During the preceding 3 months, 26 patients (4%) were admitted as inpatients. Of these, 15 patients (2%) were admitted to the neurology ward, on average 4.9 (SD 6.1) times and for a mean of 15.5 (SD Figure 1 . Proportion of patients below retirement age employed or self-employed. In all, 648 patients (90%) were below retirement age, and of these, 65% were employed or self-employed. Among these, 23 patients were on long-term absence.
EDSS: Expanded Disability Status Scale. 13.7) days. Admission to another ward was reported by 13 patients (2%). Day admissions were reported by 55 patients (8%), on average once a month. Inpatient or day admissions to rehabilitation centres occurred for 38 patients (5%).
The majority of patients (512, 71%) had a consultation during the past 3 months, most often with a neurologist (55%), a general practitioner (28%) or a physiotherapist (16%). Investigations and tests were reported by 284 patients (39%), and medications for MS and MS-related symptoms were used by 607 patients (84%) during the past month.
Drugs other than DMTs and corticosteroids were used by 134 of patients (19%), predominantly treatments for walking, spasticity and pain (13%). Non-prescription drugs were used by 310 patients (43%).
Investments in equipment and devices to aid patients' mobility were made during the past 12 months for or by 129 patients (18%), most often for modifications to the car or the house and walking aids.
Community and social services were used by 18% of patients, most frequently home help and Figure 5 ).
Costs
The total mean annual costs per patient for patients with mild, moderate and severe diseases and by EDSS score are presented in Table 4 and Figure 6 .
The average cost of a relapse for patients with an EDSS of 0 to 6 was estimated at 7643CHF. All types of costs increased during a relapse, with hospitalisation representing 58% of the additional cost (day admissions 34%, inpatient care 24%) and informal care 13% (Figure 7 ).
Discussion
This study provides an update to current understanding of the burden of MS on patients, the healthcare system and society in general in Switzerland based on a cross-sectional survey conducted in 2015.
The number of participants in the study reached the target of 50-80 patients per EDSS level (with the exception of EDSS 9), was geographically representative, with educational levels comparable to the general population, and with limited missing data due to only on-line responses. There might be a slight bias towards more patients with mild and early disease than the general prevalence, but estimates of costs and utilities by disease severity are not affected by this and can be considered representative.
Disease symptoms and utility were very similar to those found in all the other countries, attesting to the fact that the severity of the disease affects patients in the same way regardless of jurisdiction or healthcare systems. Thus, family support (informal care) was found to be at a similar level as in the other countries as well.
Most of the findings that related to symptoms and HRQoL correlated with disease severity, with the notable exception of anxiety/depression that was found to affect around half of the patients regardless of EDSS in all countries. This finding is in line with previous data indicating a 50% lifetime prevalence for affective disturbances in MS. 18 Moreover, and again in line with recent studies, psychoaffective symptoms, together with fatigue and cognitive disturbances, were the most significant determinants of productivity at work. These findings may help identify individuals at higher risk of unemployment.
Consumption of healthcare resources is generally more driven by the healthcare system and availability of services, and Switzerland was no exception. Inpatient admission was rare and limited to a small number of patients, possibly related to relapses. Neurologists saw over half and general practitioners a third of the patients in a 3-month period, while MS nurses do not seem to play a major role. With a majority of patients with mild and relapsing MS, DMT usage was correspondingly among the higher in the study series (64%), with Portugal, Spain, France and Italy reporting higher proportions. All these countries included a similar proportion of patients with limited disability and a mean EDSS below 4. For the same reason, a relatively high proportion of patients were still in employment (65% of people of working age). However, none of them worked full-time, which may have influenced this high participation rate.
Participants in the previous survey in 2005 7 were quite different: The sample was older and the majority of patients indicated that they had progressive MS. As a consequence, the group with mild disability was much smaller (38% compared to 61%), and the pattern of overall resource consumption was quite different, in particular, hospitalisation, tests (MRIs), DMTs and informal care. However, while the disease clearly has some influence on consumption, it is likely that many of the differences are more due to changes in patient management in the last decade, both in general and for MS patients in particular: less inpatient care overall, and more management with MRIs in particular and earlier treatment with DMTs. Interestingly though, the mean annual costs by EDSS are almost the same -indicating that quantities and/or prices of resources have not changed substantially.
In conclusion, these data characterise various aspects of the burden of MS on patients and society in Switzerland and capture patterns of resource utilisation that could inform future policy recommendations. In addition, these data provide input into cost-effectiveness analyses for reimbursement decisions.
